Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: Relevance of Köhne's risk classification

Digestive and Liver Disease

Volumn 45, Issue 4, 2013, Pages 330-335

  Desot, Elise ^a   de Mestier, Louis ^a   Volet, Julien ^a   Delmas, Christelle ^a   Garcia, Bruno ^b   Geoffroy, Patrick ^c   Abdelli, Naceur ^d   Baule, Marielle ^e   Dubroeucq, Olivier ^f   Marquis, Eric ^a   Bouché, Olivier ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b Polyclinique Courlancy ^*  (France)

^c Clinique Saint Vincent   (France)

^d Department of Hepato Gastroenterology   (France)

^e Centre Hospitalier Auban Moet   (France)

^f INSTITUT JEAN GODINOT   (France)

Author keywords

Colorectal neoplasm; Metastasis; Palliative chemotherapy; Prognosis

Indexed keywords

BEVACIZUMAB; CETUXIMAB; PANITUMUMAB;

ADULT; AGED; ARTICLE; BIOTHERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; DISEASE CLASSIFICATION; FEMALE; HUMAN; HUMAN TISSUE; KOHNE'S RISK CLASSIFICATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NON RESECTABLE METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; ALKALINE PHOSPHATASE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; MALE; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84875246803     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.10.016     Document Type: Article

References (27)

1. Kopetz S., Chang G.J., Overman M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. Journal of Clinical Oncology 2009, 27:3677-3683.
2. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004, 350:2335-2342.
3. Saltz L.B., Clarke S., Díaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of Clinical Oncology 2008, 26:2013-2019.
4. Van Cutsem E., Köhne C.-H., Láng I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology 2011, 29:2011-2019.
5. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine 2004, 351:337-345.
6. Van Cutsem E., Köhne C.-H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New England Journal of Medicine 2009, 360:1408-1417.
7. Douillard J.-Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Journal of Clinical Oncology 2010, 28:4697-4705.
8. Köhne C.H., Cunningham D., Di Costanzo F., et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Annals of Oncology 2002, 13:308-317.
9. Chibaudel B., Bonnetain F., Tournigand C., et al. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist 2011, 16:1228-1238.
10. Díaz R., Aparicio J., Gironés R., et al. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy. Clin Colorectal Cancer 2005, 5:197-202.
11. Ducreux M., Malka D., Mendiboure J., et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. The Lancet Oncology 2011, 12:1032-1044.
12. Sanoff H.K., Sargent D.J., Campbell M.E., et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. Journal of Clinical Oncology 2008, 26:5721-5727.
13. Kabbinavar F., Irl C., Zurlo A., Hurwitz H. Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. Oncology 2008, 75:215-223.
14. Bachet J.-B., Afchain P., Fermanian C., et al. Cetuximab efficacy in patients treated routinely in university hospitals. Gastroenterologie Clinique et Biologique 2007, 31:941-949.
15. Chibaudel B., Tournigand C., Artru P., et al. FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. Annals of Oncology 2009, 20:1383-1386.
16. Koopman M., Antonini N.F., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007, 370:135-142.
17. Seymour M.T., Maughan T.S., Ledermann J.A., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007, 370:143-152.
18. Sorbye H., Köhne C.-H., Sargent D.J., Glimelius B. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Annals of Oncology 2007, 18:1666-1672.
19. Sargent D.J., Köhne C.H., Sanoff H.K., et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. Journal of Clinical Oncology 2009, 27:1948-1955.
20. Rougier P., Milan C., Lazorthes F., et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. British Journal of Surgery 1995, 82:1397-1400.
21. Steinberg J., Erlichman C., Gadalla T., et al. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. European Cancer Journal 1992, 28A.:1817-1820.
22. Mitry E., Douillard J.-Y., Van Cutsem E., et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Annals of Oncology 2004, 15:1013-1017.
23. Shitara K., Matsuo K., Takahari D., et al. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. European Journal of Cancer 2009, 45:1757-1763.
24. Kishi Y., Kopetz S., Chun Y.S., et al. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Annals of Surgical Oncology 2009, 16:614-622.
25. Richman S.D., Seymour M.T., Chambers P., et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. Journal of Clinical Oncology 2009, 27:5931-5937.
26. Yokota T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?. Anti-cancer Agents in Medicinal Chemistry 2012, 12:163-171.
27. De Roock W., De Vriendt V., Normanno N., et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncology 2011, 12:594-603.